Literature DB >> 28905733

Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy.

Sarah E Wakeman1.   

Abstract

Due to the criminalization of drug use and addiction, opioid use disorder is overrepresented in incarcerated populations. Decades of evidence supports opioid agonist therapy as a highly effective treatment that improves clinical outcomes and reduces illicit opioid use, overdose death, and cost. Opioid agonist therapy has been both studied within correctional facilities and initiated prerelease. It has been found to be beneficial, yet few incarcerated persons receive this evidence-based treatment. In addition to not offering treatment initiation for those who need it, most correctional facilities forcibly withdraw stable patients from opioid agonist therapy upon their entry into the criminal justice system. This approach limits their access to evidence-based health care and results in negative outcomes for individuals, communities, and society.
© 2017 American Medical Association. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28905733     DOI: 10.1001/journalofethics.2017.19.9.stas1-1709

Source DB:  PubMed          Journal:  AMA J Ethics


  7 in total

1.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

2.  Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.

Authors:  C J Banta-Green; J R Williams; J M Sears; A S Floyd; J I Tsui; T J Hoeft
Journal:  Drug Alcohol Depend       Date:  2019-12-11       Impact factor: 4.492

3.  Association of Methadone Treatment With Substance-Related Hospital Admissions Among a Population in Canada With a History of Criminal Convictions.

Authors:  Angela Russolillo; Akm Moniruzzaman; Julian M Somers
Journal:  JAMA Netw Open       Date:  2019-03-01

4.  Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings.

Authors:  George Pro; Nick Zaller
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

5.  Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data.

Authors:  Morgane Rousselet; Marylène Guerlais; Pascal Caillet; Bertrand Le Geay; Damien Mauillon; Patrick Serre; Pierre-Yves Chameau; Yves Bleher; Serge Mounsande; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  PLoS One       Date:  2019-12-04       Impact factor: 3.240

6.  Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use.

Authors:  Tyler N A Winkelman; Virginia W Chang; Ingrid A Binswanger
Journal:  JAMA Netw Open       Date:  2018-07-06

Review 7.  Opioid substitution therapy for people living in German prisons-inequality compared with civic sector.

Authors:  Heino Stöver; Daniela Jamin; Ingo Ilja Michels; Bärbel Knorr; Karlheinz Keppler; Daniel Deimel
Journal:  Harm Reduct J       Date:  2019-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.